HBV相关性肝细胞癌预测模型的演变及临床意义

董菁; 江家骥

doi:10.3969/j.issn.1001-5256.2015.06.008

HBV相关性肝细胞癌预测模型的演变及临床意义

DOI: 10.3969/j.issn.1001-5256.2015.06.008

董菁,
江家骥

福建医科大学附属第一医院肝病中心

详细信息

中图分类号: R735.7;R512.62
计量
- 文章访问数: 2856
- HTML全文浏览量: 16
- PDF下载量: 573
- 被引次数: 0
出版历程
- 出版日期: 2015-06-20

Significance of predictive models / risk calculators for HBV-related hepatocellular carcinoma

摘要

摘要: HBV相关性肝细胞癌（HCC）是东南亚地区重要的公共卫生问题。近年来香港、台湾学者通过自然史研究发明了HBV相关性HCC预测模型/危险计算器,可在一定程度上预测HCC发生的可能性。年龄、性别、HBV DNA水平和肝硬化是各个模型常用的危险因素。讨论了目前几种HBV相关性HCC预测模型的演变及其临床意义,探讨了风险计算器的优缺点,更新版REACH-B模型和LSM-HCC模型具有较好的阴性预测值,可以对慢性乙型肝炎（CHB）患者预后予以较好的推测。这些模型可被用于分层筛查HCC,同时也成为管理CHB患者新的评估工具。
- 癌,肝细胞 /
- 肝炎病毒,乙型 /
- 比例危险度模型
Abstract: Hepatitis B virus( HBV)- related hepatocellular carcinoma( HCC) is a major public health problem in Southeast Asia. In recent years,researchers from Hong Kong and Taiwan have reported predictive models or risk calculators for HBV- associated HCC by studying its natural history,which,to some extent,predicts the possibility of HCC development. Generally,risk factors of each model involve age,sex,HBV DNA level,and liver cirrhosis. This article discusses the evolution and clinical significance of currently used predictive models for HBV- associated HCC and assesses the advantages and limits of risk calculators. Updated REACH- B model and LSM- HCC model show better negative predictive values and have better performance in predicting the outcomes of patients with chronic hepatitis B( CHB). These models can be applied to stratified screening of HCC and,meanwhile,become an assessment tool for the management of CHB patients.
- carcinoma,hepatocellular /
- hepatitis B virus /
- proportional hazards models

HTML全文

参考文献(17)

[1]MITTAL S,El-SERAG HB.Epidemiology of hepatocellular carcinoma:consider the population[J].J Clin Gastroenterol,2013,47(Suppl):s2-s6.

[2]WONG GL,WONG VW,TAN GM,et al.Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis[J].Liver Int,2008,28(1):79-87.

[3] BRUIX J,SHERMAN M.Management of hepatocellular carcinoma:an update[J].Hepatology,2011,53(3):1020-1022.

[4]YUEN MF,TANAKA Y,FONG DY,et al.Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B[J].J Hepatol,2009,50(1):80-88.

[5]YANG JD,KIM WR,COELHO R,et al.Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma[J].Clin Gastroenterol Hepatol,2011,9(1):64-70.

[6]HAN KH,AHN SH.How to predict HCC development in patients with chronic B viral liver disease?[J].Intervirology,2005,48(1):23-28.

[7] WONG VW,CHAN SL,MO F,et al.Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers[J].J Clin Oncol,2010,28(10):1660-1665.

[8]WONG GL,CHAN HL,WONG CK,et al.Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B[J].J Hepatol,2014,60(2):339-345.

[9]YANG HI,SHERMAN M,SU J,et al.Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection[J].J Clin Oncol,2010,28(14):2437-2244.

[10]YANG HI,YUEB MF,CHAN HL,et al.Risk estimation for hepatocellular carcinoma in chronic hepatitis B(REACH-B):development and validation of a predictive score[J].Lancet Oncol,2011,12(6):568-574.

[11]LEE MH,YANG HI,LIU J,et al.Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients:risk scores integrating host and virus profiles[J].Hepatology,2013,58(2):546-554.

[12]PAPATHEODORIDIS GV,DALEKOS GN,YURDAYDIN C,et al.Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir[J].J Hepatol,2015,62(2):363-370.

[13]YANG HI,LEE MH,LIU J,et al.Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia[J].World J Gastroenterol,2014,20(20):6244-6251.

[14]KAO JH.Risk stratification of HBV infection in Asia-Pacific region[J].Clin Mol Hepatol,2014,20(3):223-227.

[15]WONG GL,CHAN HL,CHAN H,et al.Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment[J].Gastroenterology,2013,144(5):933-944.

[16]COFFIN CS,REZAEEAVAL M,PANG JX,et al.The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy[J].Aliment Pharmacol Ther,2014,40(11-12):1262-1269.

[17]DONG J,JIANG JJ.Screening and the effect of antiviral therapy for hepatitis B virus related hepatocellular carcinoma[J].Chin J Viral Dis,2013,3(6):474-479.(in Chinese)董菁,江家骥.乙型肝炎病毒相关性肝细胞癌的筛查及抗病毒治疗的应用[J].中国病毒病杂志,2013,3(6):474-479.

施引文献

资源附件(0)

访问统计